Behold.ai

Behold.ai offers two core products powered by its proprietary red dot® technology: the red dot® Lung Cancer Detection Platform and the red dot® CTH V1. The Lung Cancer Detection Platform is designed to automatically identify normal scans and triage potential lung cancer cases to support clinical decision-making. The red dot® CTH V1 enables 24/7 triage of acute findings and can rule out normal CT head exams to support urgent care pathways. The product is intended for use in diagnostic imaging for CT and X-ray, with the stated purpose of detecting critical conditions such as lung cancer and stroke. According to the source, the platform has undergone clinical validation involving over 32,000 patients, with a reported outcome of zero missed lung cancers over three years using its Rule-Out AI. It is approved by both the FDA and CE. Real-world case studies from NHS Trusts are cited: at Calderdale and Huddersfield NHS Foundation Trust, the service reduced waiting times for suspected lung cancer patients by 71%; at an Essex hospital, it reduced a chest X-ray backlog from 4-8 weeks to 3.5 days. The platform is also noted to be in use at Apollo Hospitals in India and for AI pneumothorax triage in the US.